Sort   by:  
 Page size 
UnknownPhase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma.
Not available
S-EPMC6804828 | biostudies-literature
UnknownEpidemiology and economic burden of Von Hippel-Lindau Disease-associated central nervous system hemangioblastomas and pancreatic neuroendocrine tumors in the United States.
Not available
S-EPMC10873931 | biostudies-literature
UnknownMK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma.
Not available
S-EPMC8268068 | biostudies-literature
UnknownSystemic Therapy Development in Von Hippel-Lindau Disease: An Outsized Contribution from an Orphan Disease.
Not available
S-EPMC9658616 | biostudies-literature
UnknownClear cell renal cell carcinoma ontogeny and mechanisms of lethality.
Not available
S-EPMC8172121 | biostudies-literature
UnknownAdjuvant and neoadjuvant therapy in renal cell carcinoma.
Not available
S-EPMC3895463 | biostudies-literature
UnknownRenal cell carcinoma.
Not available
S-EPMC4707715 | biostudies-literature
UnknownCombination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?
Not available
S-EPMC8833428 | biostudies-literature
UnknownPlasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma.
Not available
S-EPMC5522056 | biostudies-literature
UnknownHypoxia-Associated Factor (HAF) Mediates Neurofibromin Ubiquitination and Degradation Leading to Ras-ERK Pathway Activation in Hypoxia.
Not available
S-EPMC6497562 | biostudies-literature
Sort   by:  
 Page size